MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction

Inclusion Criteria: Men who underwent robotic bilateral nerve-sparing radical prostatectomy between 18 and 36 months prior to study commencement Subjects are 18-36 months status-post radical prostatectomy Subjects have any degree of erectile dysfunction based on IIEF questionnaire Age 40 - 70 at study commencement Diagnosed with low/intermediate-risk prostate cancer: PSA < 20 ng/ml Gleason score =< 8 Prostate Cancer stage =< T2b Normal pre-radical prostatectomy erectile function (IIEF >=26) Baseline erectile dysfunction at time of screening (despite use of erectogenic aids of any kind) and enrolment following washout (IIEF-ED domain <=25) Sexually active, in a stable heterosexual relationship for at least 6 months prior to screening Able to understand and complete patient questionnaires Serum prostate specific antigen (PSA) undetectable (no evidence of disease recurrence) Able to consent to participate Documented written informed consent from both patient and his female partner Exclusion Criteria: Anatomical abnormalities in the genitalia or pelvic region such as severe phimosis Post-Radical Prostatectomy complications that could impact safety or effectiveness of medical therapy for erectile function (treatment for pelvic hematoma, urinary or intestinal fistula, unresolved anastomotic leak) Incomplete tumor removal (positive surgical margin) Tumor upstaging beyond T2b Incomplete / sub-total nerve sparing on either side Previous or scheduled treatment with pelvic salvage radiotherapy and/or androgen deprivation therapy Prior receipt of androgen deprivation therapy Any other condition that would prevent the patient from completing the study, as judged by the Principal Investigator